Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT03817190. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to compare the efficacy and safety of orally administered DS107 (2g) versus placebo in the treatment of moderate to severe Atopic Dermatitis (AD). Oral DS107/Placebo capsules will be administered for 16 weeks. The study will enrol approximately 220 subjects.
Study identification
- NCT ID
- NCT03817190
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 219 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 19, 2019 (Actual)
- Primary completion
- Sep 3, 2020 (Actual)
- Completion
- Sep 3, 2020 (Actual)
- Last update posted
- Nov 28, 2022
2019 – 2020
United States locations
- U.S. sites
- 26
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| DS Investigational Site 524 | Birmingham | Alabama | 35209 | — |
| DS Investigational Site 528 | Huntington Beach | California | 92647 | — |
| DS Investigational Site 502 | Los Angeles | California | 90045 | — |
| DS Investigational Site 504 | San Diego | California | 92108 | — |
| DS Investigational Site 505 | San Diego | California | 92123 | — |
| DS Investigational Site 516 | Santa Ana | California | 92705 | — |
| DS Investigational Site 501 | Santa Monica | California | 90404 | — |
| DS Investigational Site 517 | Washington D.C. | District of Columbia | 20037 | — |
| DS Investigational Site 527 | Doral | Florida | 33122 | — |
| DS Investigational Site 510 | Sunrise | Florida | 33351 | — |
| DS Investigational Site 512 | Columbus | Georgia | 31904 | — |
| DS Investigational Site 514 | Skokie | Illinois | 60077 | — |
| DS Investigational Site 513 | Louisville | Kentucky | 40241 | — |
| DS Investigational Site 519 | Troy | Michigan | 48084 | — |
| DS Investigational Site 511 | Raleigh | North Carolina | 27612 | — |
| DS Investigational Site 526 | Grants Pass | Oregon | 97527 | — |
| DS Investigational Site 521 | Medford | Oregon | 97504 | — |
| DS Investigational Site 525 | Philadelphia | Pennsylvania | 19046 | — |
| DS Investigational Site 509 | Arlington | Texas | 76011 | — |
| DS Investigational Site 506 | Austin | Texas | 78745 | — |
| DS Investigational Site 508 | Cypress | Texas | 77433 | — |
| DS Investigational Site 507 | San Antonio | Texas | 78213 | — |
| DS Investigative Site 529 | Orem | Utah | 84058 | — |
| DS Investigative Site 530 | Salt Lake City | Utah | 84117 | — |
| DS Investigational Site 523 | Richmond | Virginia | 23224 | — |
| DS Investigational Site 518 | Kenosha | Wisconsin | 53144 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03817190, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 28, 2022 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03817190 live on ClinicalTrials.gov.